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Abstract
CD44 is a cell surface glycoprotein that functions as hyaluronan receptor. Mouse and human serum contain substantial
amounts of soluble CD44, generated either by shedding or alternative splicing. During inflammation and in cancer patients
serum levels of soluble CD44 are significantly increased. Experimentally, soluble CD44 overexpression blocks cancer cell
adhesion to HA. We have previously found that recombinant CD44 hyaluronan binding domain (CD44HABD) and its non-
HA-binding mutant inhibited tumor xenograft growth, angiogenesis, and endothelial cell proliferation. These data
suggested an additional target other than HA for CD44HABD. By using non-HA-binding CD44HABD Arg41Ala, Arg78Ser, and
Tyr79Ser-triple mutant (CD443MUT) we have identified intermediate filament protein vimentin as a novel interaction
partner of CD44. We found that vimentin is expressed on the cell surface of human umbilical vein endothelial cells (HUVEC).
Endogenous CD44 and vimentin coprecipitate from HUVECs, and when overexpressed in vimentin-negative MCF-7 cells. By
using deletion mutants, we found that CD44HABD and CD443MUT bind vimentin N-terminal head domain. CD443MUT
binds vimentin in solution with a Kd in range of 12–37 nM, and immobilised vimentin with Kd of 74 nM. CD443MUT binds
to HUVEC and recombinant vimentin displaces CD443MUT from its binding sites. CD44HABD and CD443MUT were
internalized by wild-type endothelial cells, but not by lung endothelial cells isolated from vimentin knock-out mice.
Together, these data suggest that vimentin provides a specific binding site for soluble CD44 on endothelial cells.
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Introduction
CD44 transmembrane glycoprotein functions as hyaluronan (HA)
receptor. CD44 has functions in a lymphocyte homing, mediates cell
adhesion to HA and HA metabolism. CD44 is expressed on many
cell types including endothelial cells (EC) and has multiple
alternatively spliced isoforms. CD44 plays a significant role in tumor
malignancy. High levels of CD44 expression on tumor cells is
sufficient to establish metastatic behavior [1,2]. CD44 is involved in
pathological angiogenesis, as its expression is elevated in tumor
vasculature, and CD44 expression can be induced in cultured ECs
byangiogenic growth factors [3] Furthermore, CD44 knockout mice
showreducedvascularisationoftumorxenograftsandMatrigelplugs
[4]. In addition to cell surface expression, CD44 is present in soluble
form in lymph and serum [5] or bound to extracellular matrix [6].
Soluble CD44 is generated either by alternative splicing [7] or, more
importantly, by ectodomain shedding by matrix metalloproteases
[8,9].The size of shed CD44 is highly heterogeneous because of
glycosylations and variant exons [5,9–11]. The serum concentration
ofsCD44 inmiceisknowntorange between 490 to 2100 ng/ml[5].
StudiesofsCD44intheseraofnon-Hodgkin’slymphomaand breast
cancer patients show that physiological sCD44 level in healthy
persons is in the range of 250 to 500 ng/ml [12–14]. The serum
concentration of sCD44 in healthy individuals is ,3 nM whereas it
was shown to be significantly elevated in patients with advanced
gastric (24 nM) or colon cancer (31 nM) [11]. Elevated serum
sCD44 or sCD44v6 is a predictor of poor therapeutic outcome in
non-Hodgkin’s lymphoma or breast cancer patients, respectively
[12,15].The source of sCD44 are lymphocytes, macrophages, ECs,
and tumor cells [10,11,16]. In non-Hodgkin’s lymphoma, the source
of elevated sCD44 are lymphoma cells, and sCD44 levels decrease
after treatment in patients with complete remission [10,17].
Endothelial and macrophage CD44 expression is increased in
atheromas and CD44 shedding from EC and macrophages is
stimulated by proinflammatory cytokines [16].
Tumors are surrounded by HA-rich ECM. When overex-
pressed in tumor cells, soluble CD44 can function as an antagonist
to cell membrane CD44 and block its binding to ECM HA.
Overexpression of soluble forms of CD44 inhibits HA-adhesion of
mouse mammary carcinoma or melanoma cells and caused
inhibition of tumor cell proliferation, and reduced tumorigenicity
[18–20]. CD44 knockout in mouse breast cancer model caused
increased numbers of lung metastases, which correlated with
reduced invasion of CD44-expressing metastatic breast cancer cell
lines into HA-containing collagen matrixes [21].
CD44 binds HA via the link module in its N-terminal domain.
The link module is approximately 100 amino acids long and
consists of two alpha helices and two triple-stranded antiparallel
beta sheets, stabilized by two disulphide bridges [22]. The
structure of CD44 HABD has an additional lobe consisting of
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29305four beta strands formed by the residues flanking the core link
module [23,24]. This enlarged structure is stabilized by an
additional disulphide bridge between flanking regions. Together,
the human CD44 HABD structure consists amino acids 21–169.
The HA-binding surface of CD44 is exclusively covered by the link
module and its flanking regions do not contribute to the HA
binding [23]. The critical residues in CD44 HA-binding surface
directly involved in binding are Arg41, Tyr42, Arg78, and Tyr79,
according to studies of human CD44 [23,25]. Glycosylation of
Asn25 and Asn125 within CD44 HABD is involved in regulation
of HA binding [26]. Altogether, CD44 has five N-glycosylation
sites (Asn25, Asn57, Asn100, Asn110, Asn120) within its HABD.
Bacterially expressed recombinant human CD44 HABD contain-
ing amino acids 20–178 binds HA comparably to glycosylated
CD44-Rg fusion protein [24]. HA binding function is also retained
by a recombinant human CD44HABD containing amino acids
21–132, whereas HA binding was abolished by the mutations in
Arg41, Arg78, and Tyr79 [27].
Vimentin intermediate filaments comprises supporting frame-
work within cells. Vimentin functions in intracellular vesicular
transport, including b1-integrin trafficking [28], transport of
lysosomal membrane proteins by binding AP-3 complex [29], and
as a cytosolic reservoir for tSNARE SNAP23 [30]. Importantly,
vimentin knockout cells apparently retain intact receptor-mediated
endocytosis, as transferrin receptor level and distribution is normal
[29,30]. Vimentin-deficient mice reproduce and develop normally
[31], however, they show reduced elasticity of arteries, decreased
nitric oxide production and elevated endothelin [32,33]. Vimentin
is expressed on cell surface in several cell types, including TNF-a
induced macrophages [34], cutaneous T-cell lymphoma [35],
platelets [36], and brain microvascular endothelial cells [37].
Vimentin extracellular ligands include vitronectin/PAI-1 complex
[36], and E. coli IbeA protein [37]. Vimentin is a antiangiogenesis
target overexpressed on tumor endothelium in vivo. Anti-vimentin
antibody treatment inhibited subcutaneous tumor xenograft growth
and tumor blood vessel density in mice, suggesting that vimentin is
localized to the cell surface in tumor endothelial cells [38].
CD44and vimentinare bothdetectablefrom membranelipid raft
fractions [39–41] and from clathrin-independent pathway endocytic
vesicles in fibroblasts [42]. CD44 and vimentin are upregulated
during epithelial-mesenchymal transition (EMT) of cancer cells.
Mammary epithelial cells undergoing EMT downregulate epithelial
genes and upregulate mesenchymal genes, such as E-cadherin, N-
cadherin and vimentin, respectively. Suppression of standard CD44
isoform in Snail- or TGF-b-induced human mammary epithelial
cells inhibits EMT, accompanied by vimentin downregulation [43].
We have previously found that recombinant CD44 HABD 21–
132, as a model for soluble CD44, inhibited human subcutaneous
tumor xenograft growth in mice, angiogenesis in chick chorio-
allantoic membrane, and EC proliferation [27]. Surprisingly, these
CD44HABD functions were independent of its HA-binding
propery, as non-HA-binding mutant was similarly effective.
Therefore, we proposed that CD44HABD could bind additionally
to a different ligand than HA. In this study, we used CD44HABD
non-HA-binding mutant as a bait in GST pull-down assay and
identified vimentin as a novel CD44 interacting protein.
Results
Identification of vimentin as CD44 HABD-binding protein
To identify EC target of CD44 HABD 21–132 (CD44HABD)
and its non-HA-binding mutant CD44HABD
R41AR78SY79S
(CD443MUT), we used GST pull-down from HUVEC lysate.
Silver staining of pull-down reactions separated by SDS-PAGE
revealed that GST-tagged CD443MUT precipitated a 60 kD
protein (Figure 1A). This protein was identified by MALDI-TOF-
MS protein fingerprinting as vimentin. To confirm that
CD44HABD-proteins pull down vimentin, we used anti-vimentin
(V9) immunoblotting. Immunoblotting confirmed that GST-
tagged CD44HABD and CD443MUT pulled down endogenous
vimentin from HUVEC lysates (Figure 1B, upper panel). To
determine whether CD44HABD and CD443MUT bind vimentin
directly, we used recombinant vimentin in the GST pull-down
assay. We found that both CD44HABD and CD443MUT were
able to pull down recombinant vimentin, suggesting that CD44
interacts with vimentin directly (Figure 1B, lower panel). We next
used immunoprecipitation (IP) to determine whether endogenous
CD44 and vimentin associate in EC. HUVEC lysate was
immunoprecipitated using anti-CD44 (MEM-263) antibody and
immunoprecipitates were subsequently analyzed by immunoblot-
ting. We found that a minor population of vimentin coimmuno-
precipitated with CD44 from HUVEC lysate (Figure 1C). We also
tested whether anti-vimentin antibodies coimmunoprecipitate
CD44. However, we were not able to detect CD44 from anti-
vimentin IPs (A.P., unpublished data). To further confirm full-
length CD44 and vimentin association we overexpressed C-
terminally Flag-tagged CD44 standard isoform and Myc-tagged
vimentin in vimentin nonexpressing MCF-7 cells. Overexpressed
vimentin was exposed to the cell surface as detected by cell surface
biotinylation (Figure S1). Immunoprecipitation results showed that
anti-Flag immunoprecipitated a vimentin-Myc from CD44-Flag
transfected cells (Figure 1D).
Vimentin and CD443MUT in vitro binding affinity
CD443MUT interaction with recombinant full length human
vimentin was further characterized by isothermal titration
calorimetry (ITC) and by surface plasmon resonance (SPR). We
used two different preparations of CD443MUT. ITC experiments
showed that CD443MUT binds to recombinant vimentin with Kd
in 12–37 nM range with stoichiometry (vimentin/CD443MUT) of
<7 mol/mol (Table 1). SPR experiments were carried out with
vimentin immobilized into measuring cell. Kinetic analysis by SPR
revealed that binding of CD443MUT to immobilized vimentin is
described by a two-site ligand binding model. CD443MUT bound
to a high-affinity site of immobilized vimentin with Kd 74 nM and
Kd for low affinity site was 15 mM (Table 2). Analysis of kinetic
data using equilibrium response values resulted in 1562 mM Kd.
The stoichiometry of vimentin/CD443MUT complex in SPR
experiment was measured<6 mol/mol .
Mapping of vimentin CD44-binding region
To map CD44-binding region in vimentin, we generated
truncated vimentin constructs (Figure 2A). Vimentin deletion
mutant VIM1-96 contains only head domain, VIM1-245 contains
head domain and alpha-helices 1A-B, and VIM97-466 mutant
lacks the head domain (aa numbering according to human
vimentin). VIM246-466 mutant contains C-terminal half of the
protein starting from alpha-helices 2A-B. VIM407-466 contains
the tail domain. Lysates of MCF-7 cells, expressing either full-
length vimentin or its deletion mutants, were used in GST pull-
down with CD44HABD or CD443MUT. Pull-downs were
analyzed by immunoblotting using tag-specific antibodies. This
analysis showed that CD44HABD and CD443MUT bound only
vimentin deletion mutants containing the head domain (VIM1-96
and VIM1-245; Figure 2B). Deletion of the head domain was
sufficient to abolish binding of vimentin to CD44HABD and
CD443MUT(VIM97-477, VIM246-466 or VIM407-466).
CD44 Binds Vimentin
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interaction is induced by VEGF
To detect cell surface vimentin, we performed biotinylation of
cell surface proteins of adherent living HUVEC, followed by IP of
vimentin from cell lysates. Biotinylated proteins were detected by
immunoblotting using HRP-conjugated strepavidin. We found
that anti-vimentin (V9) antibody immunoprecipitated from
HUVEC lysate a 60 kD biotinylated protein. We used anti-
CD44 (H4C4) antibody as positive control and found that it IPd a
100 kD biotinylated protein. These proteins correspond to
expected sizes of vimentin and endothelial CD44, respectively
(Figure 3A upper panel). The identity of biotinylated proteins was
confirmed by immunoblotting with vimentin- or CD44-specific
antibodies (Figure 3A lower panel).
Next, we decided to test whether CD443MUT cellular binding
can be induced with angiogenic growth factors. To determine the
effect of angiogenic stimulus on CD443MUT cellular binding we
induced 6 h serum starved HUVEC 30 min with VEGF165 at
37uC. Then we incubated cells with Alexa Fluor 488-labeled
CD443MUT at 4uC. CD443MUT-A488 cellular binding was
quantitated using flow cytometry. We found a significant binding
of CD443MUT-A488 to HUVEC compared to GST-A488
control (P=0.015, n=3, unpaired t-test). Under these conditions
,20% cells bound CD443MUT. VEGF treatment induced a
further increase in CD443MUT cellular binding compared to
non-induced cells, although this result was statistically marginally
significant (P=0.067, n=3; Figure 3B). To confirm that VEGF
induces cell surface vimentin binding sites for CD443MUT, we
used cell surface biotinylation of HUVEC followed by GST pull-
down with CD443MUT. For this, overnight serum starved
HUVEC were induced 1 hour with VEGF or left non-induced,
followed by cell surface biotinylation of live adherent cells. GST-
CD443MUT or GST alone were used in pull-downs from cell-
surface biotinylated HUVEC lysates. Subsecuently, precipitated
proteins were detected by western blotting either by strepavidin-
HRP or anti-vimentin (V9) antibody. We found that CD443MUT
pulled down a 60 kD biotinylated protein from VEGF-stimulated
but not from serum starved cells. This protein turned out to be
vimentin since it could be detected with a vimentin-specific
antibody (Figure 3C).
Vimentin displaces CD443MUT from HUVEC
To further characterize CD443MUT and vimentin interaction
on HUVECs we measured the ability of vimentin to compete with
125I-labeled CD443MUT for cellular binding. The results of
displacement binding experiments showed that CD443MUT
displaced itself from HUVEC with logEC50 25.860.05 M
(EC50=1.57 mM, n=9; Figure 3D). Vimentin displaced
CD443MUT from HUVEC with logEC50 25.3760.21 M
(EC50=4.26 mM , n=2) which is not significantly different from
displacement by CD443MUT itself (extra sum of squares F-test,
P=0.0711; F=3.298 (1,171)). BSA did not displace CD443MUT
effectively, with logEC 23.9360.06 M (EC50=117 mM, n=4).
CD44HABD endocytosis by HUVEC
Given that vimentin provides specific binding site for
CD443MUT on EC, we decided to test whether CD443MUT is
endocytosed upon binding to cell surface vimentin. We incubated
HUVEC with unlabeled CD443MUT for 30 min at 37uC to allow
internalization. CD443MUT was detected by immunofluores-
cence confocal microscopy using CD443MUT specific mouse
monoclonal antibody 1A2 (Figure S2). Recombinant GST uptake
Table 1. Summary of Kd values for CD443MUT and vimentin interaction measured by ITC.
CD443MUT preparation CD443MUT (mM) Vimentin (mM) Kd (M) n
a (mol/mol)
A 4.2 1.8 1.2?1028610299 . 9 60.5
1.5 0.5 3.7?102861029
B 4.2 1.8 1.8?1028610297 . 2 60.3
0.9 0.5 2.3?102861029
a, stoichiometry (vimentin/CD443MUT).
doi:10.1371/journal.pone.0029305.t001
Figure 1. Identification of vimentin as CD44HABD-binding
protein. (A) HUVEC lysate was used in GST pull-down to identify
CD443MUT interacting proteins. Lysate was incubated with GST-
CD443MUT (GST-3MUT) coated beads. Bound proteins were eluted
using reduced glutathione and analyzed by SDS-PAGE and silver
staining. GST-3MUT precipitated protein band (shown by arrow) was
cut off from gel, trypsinolyzed and analyzed by MALDI-TOF MS. This
protein was identified as vimentin. (B, upper panel) Vimentin pull-down
by CD44HABD (GST-HABD) and GST-3MUT was confirmed by immuno-
blotting using anti-vimentin V9 antibody. (B, lower panel) GST-HABD
and GST-3MUT pull-down recombinant vimentin. (C) Coimmunopreci-
pitation of vimentin with CD44 from HUVEC lysate. Anti-HDAC-1
antibody was used as a negative control (see Materials and methods).
(D) Coimmunoprecipitation of over-expressed vimentin-Myc with CD44-
Flag from MCF-7 lysates using tag-specific antibodies.
doi:10.1371/journal.pone.0029305.g001
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readily endocytosed by HUVEC and displayed a vesicular
localization pattern (Figure 4A). Next, we used CD443MUT
directly conjugated to Alexa Fluor 568 for internalization assay.
CD443MUT-A568 was endocytosed and distributed in HUVEC
cytoplasm similarly to unlabeled CD443MUT (Figure 4B).
HUVECs express vimentin at high level, and endocytosed
CD443MUT-containing vesicles were surrounded by a dense
network of vimentin intermediate filaments, however, there was no
direct colocalization of CD443MUT with vimentin filaments
(Figure 4A and B).
Next, we used a generic endocytosis marker cholera toxin B
conjugated to Alexa Fluor 555 (CTxB-A555) to trace CD443MUT
following endocytosis. We found that after 30 min uptake Alexa
Fluor 488-labeled CD44HABD as well as -3MUT colocalized with
CTxB-A555 positive structures (Figure 5A). We quantitated
colocalization of CTxB with CD44HABD and CD443MUT from
single slices of confocal image stacks as described in Materials and
Methods.Altogether,,2.6?10
4CTxB-positivevesicleswereanalyzed
from CD44HABD- (n=39) or CD443MUT-incubated cells (n=38).
As shown in Figure 5B, approximately 4–5% of CTxB-vesicles
colocalized and showed positive correlation with CD44HABD
(average Pearson’s r=0.469, 95% CI 0.438 to 0.498, df=679,
P,0.0001) or CD443MUT (r=0.532, 95% CI 0.503 to 0.531,
df=608, P,0.0001). We next analyzed CD443MUT-A488 coloca-
lization with early endosome marker EEA1 in HUVEC after 10 min
uptake followed by 20 min chase. We found that CD443MUT-A488
showed extensive colocalization with EEA1-positive vesicles after
10 min incubation (Figure 5C). Quantitation of CD443MUT and
EEA1 colocalization in ,6.5?10
3 EEA1-endosomes showed that
32% of EEA1-endosomes colocalized with CD443MUT after
10 min incubation (r=0.311, 95% CI 0.266 to 0.355, df=407,
P,0.0001), whereas a fraction of EEA1-endosomes showing
colocalization falled to 7% after 20 min chase (r=0.321, 95% CI
0.251 to 0.388, df=172, P,0.0001) following the incubation
(Figure 5D). The number of CD443MUT-vesicles in cells reduced
during 20 min chase by ,7.5 times (Figure 5D, rightmost panel)
suggesting trafficking of CD44 to late endosomal-lysosomal degra-
dation pathway. Therefore, we next analyzed whether CD443MUT
is targeted to the CD63-positive late endosomal compartment after
20 min chase following a 10 min pulse with CD443MUT-A488.
However, we found that CD443MUT-A488 showed no significant
accumulation within anti-CD63 staining vesicles after 20 min
(Figure 5E) or 50 min chase (data not shown). Together, these results
indicate that recombinant CD44HABD and CD443MUT are
endocytosed and reach early endosomal compartment.
CD443MUT endocytosis is inhibited in ECs derived from
vimentin-null mice
To test directly whether vimentin mediates CD443MUT
internalization, we isolated lung endothelial cells from wild-type
Table 2. Kinetic parameters for binding of CD443MUT to vimentin measured by SPR.
Kass1 (M
21 s
21)610
3 Kass2 (M
21 s
21)K d i s s 1 ( s
21)610
24 Kdiss2 (s
21)610
23 Kd (mM) Kdiss1/Kass1 Kd (mM) equation 1 n (mol/mol)
7.660.1 183675 . 6 60.1 1.960.1 0.074 1562 6.2
doi:10.1371/journal.pone.0029305.t002
Figure 2. CD443MUT binds vimentin N-terminal head domain. (A) A diagram of vimentin sub-domains and deletion mutants used in pull-
down reactions. Ellipses represent alpha-helices in coiled-coil domains and L1-L2 mark linker regions. GFP, green fluorescent protein. (B) GST pull-
down reactions were performed from cell lysates transfected with full length vimentin or its deletion mutants (see Materials and methods). Eluates
from pull-downs were analyzed by immunoblotting.
doi:10.1371/journal.pone.0029305.g002
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mouse lung endothelial cells (MLEC) for endothelial-specific cell
surface markers by flow cytometry (Figure 6B). FACS staining
showed that PECAM-1 and CD44 were expressed on vimentin-null
MLEC at levels comparable to WT cells. However, ICAM-2
expression was reduced on vimentin-null MLEC compared to WT
cells. We next tested the internalization of CD443MUT-A568 by
MLEC. We found that WT MLEC endocytosed CD443MUT
comparably to HUVEC after 30 min uptake,whereas CD443MUT
uptake by MLECs isolated from vimentin-null mice was inhibited
(Figure 6C).
Discussion
We have identified vimentin as a novel CD44 binding protein.
Our results – the fact that recombinant CD44HABD and
CD443MUT pulled down both endogenous as well as recombinant
vimentin, and the finding that vimentin displaces CD443MUT
boundtoHUVECcells,suggestthatCD44-vimentininteractionisa
direct protein-protein interaction. To our knowledge, CD44-
vimentin interaction is the first protein-proteininteractiondescribed
for CD44 HABD. CD44 HABD mediates low affinity interactions
with its ECM ligand HA with an in vitro Kd of 50 mM [23]. CD44 is
a membrane glycoprotein and interacts via its glycosylated variant
exons with various extracellular ligands, including fibronectin,
collagen XIV, E-selectin and osteopontin [44–47]. CD44 HABD
contains five N-linked glycosylation sites [48]. Our experiments,
where glycosylated EC-endogenous or tumor cell over-expressed
full-length CD44 immunoprecipitated vimentin correlate with our
initial findings obtained with soluble recombinant CD44HABD or
CD443MUTand stronglysuggest that post-translationallymodified
CD44 can also form a complex with vimentin. However, we were
not able to detect full-length CD44 in anti-vimentin antibody
immunoprecipitates from HUVEC lysates, which can be explained
by the fact that while HUVEC express high levels of vimentin, only
a small fraction forms a complex with membrane bound CD44.
We found that CD44 HABD binds to vimentin within its head
domain. Vimentin head-domain interactions include ankyrin
binding at the plasma membrane [49], vimentin head-domain is
also important in filament formation [50]. Our finding that CD44
binds to vimentin head domain is consistent with the proposed
Figure 3. VEGF induces cell surface vimentin and CD443MUT cellular binding. (A) For detection of cell surface vimentin, asynchronously
growing live adherent HUVEC were cell surface biotinylated and lysate was used for immunoprecipitation using anti-vimentin or anti-CD44
antibodies. Immunoprecipitated proteins were detected by immunoblotting using strepavidin-HRP (upper panel) or specific antibodies (lower
panels). (B) 6 hour serum-starved HUVEC were induced for 30 min with VEGF165, followed by incubation on ice with Alexa Fluor 488-labeled
CD443MUT (3MUT). GST Alexa Fluor 488 conjugate was used as negative control. Cellular binding of A488-conjugated proteins was analyzed by
FACS. Bars represent average geomean of fluorescence from three experiments (mean 6 SE). (C) Overnight serum-starved HUVEC were induced for
1 hour with VEGF165, followed by cell surface biotinylation. Lysate from biotinylated cells was used in pull-down using GST-3MUT. Precipitated
proteins were detected by immunoblotting using strepavidin-HRP (upper panel) or anti-vimentin antibody (lower panel). (D) For displacement assay,
cells were resuspended in incubation buffer in 96-well plate. CD443MUT, vimentin or BSA at different concentrations was added to the wells along
with
125I-labeled CD443MUT. Reactions were incubated overnight at 4uC. After incubation, reactions were stopped by filtration through glass fiber
filters blocked with BSA. Filters were washed with PBS and bound radioactivity was measured using gamma counter. The curves represent global
fitting of normalized radioligand binding data from two to nine experiments.
doi:10.1371/journal.pone.0029305.g003
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laterally into tetramers in a fashion whereby first halves of
antiparallel coiled-coil domains overlap. Physiologically, vimentin
forms a non-polar 32-meric unit-length filaments (ULF) consisting
of 16 dimers or 8 tetramers [51]. The observed stoichiometries of
6–10 moles of vimentin per one mole CD443MUT probably
reflects the number of head domains available on the ULF surface.
The Kd values calculated from SPR data (12–37 nM) for the high
affinity binding site are about 2–5 times higher than Kd-s resulting
from ITC experiments (74 nM). Such experimental discrepancy
can be explained either by limited dynamics of the immobilized
vimentin or by sterical hindrances in the environment of the SPR
chip. Currently the exact model of vimentin binding of CD44 or
whether its binding site coincides with the HA binding surface, is
not known. However, our data show that pharmacophores for
HA-binding are not necessary for vimentin binding. Our data
suggest a protein-protein interaction model which is constrained
by the fact that CD44 is a type I membrane receptor and vimentin
is a cytoplasmic intermediate filament protein. Nevertheless,
several independent findings make this interaction spaciotempo-
rally feasible. In addition to generation of CD44 intracellular
domain resulting from shedding, full-length CD44 is also
endocytosed and transported to the nucleus via NLS located in
its intracellular domain [52,53]. In this process CD44 acts as
scaffold for STAT3 and p300 [53]. Importantly, leptomycin B
induces CD44 nuclear accumulation, suggesting a nuclear-
cytoplasmic shuttling [52]. On the other hand, cell surface
vimentin is a well-known phenomenon without any known
function. We show that cell surface vimentin is readily detectable
in primary human endothelial cells, in addition to its previously
reported presence in malignant lymphocytes, activated macro-
phages and platelets [34–36]. Vimentin provides bacterial binding
sites on the surface of human brain endothelial cells [37]. Our
results suggest that vimentin might provide a binding site for
soluble CD44 on EC. This is supported by our result that
exogenously added vimentin can efficiently displace CD443MUT
from ECs. In addition, we found that CD443MUT EC binding
was enhanced by VEGF. These results were confirmed by
experiments of cell surface biotinylation of starved or VEGF-
induced ECs showing that CD443MUT was able to pull-down
biotinylated vimentin from VEGF-treated but not from serum
starved ECs. The discrepancy between the binding of
CD443MUT to starved EC in cellular binding experiment and
lack of any detectable biotinylated vimentin in pull-downs from
starved EC could be explained by the different length of serum
starvation in these experiments (6 h v. over-night, respectively).
We suggest that the physiological relevance of these results is
supported by findings that vimentin and CD44 are up-regulated
on tumor endothelial cells, whereas vimentin has been proposed as
a potential anti-angiogenesis target [3,38].
Here we show that after binding CD44HABD and its non-HA-
binding triple mutant are endocytosed by ECs. A fraction of
CD44HABD-proteins colocalized with generic endocytosis tracer
CTxB-positive vesicles and were targeted to early endosomal
structures. Importantly, we found that CD443MUT uptake was
lost in vimentin knock-out endothelial cells, suggesting further that
such internalization is mediated by vimentin. The number of
CD443MUT-positive vesicles and early-endosomal localization
decreased rapidly, most probably suggesting its targeting to
lysosomal degradation. However, we were not able to detect
significant accumulation of fluorescently labeled CD443MUT
within late endosomal compartment.
We propose that vimentin forms a complex with full-length
CD44. In this model, soluble CD44 antagonizes binding of
membrane CD44 to vimentin. However, the role for soluble
CD44 in tumorigenesis still remains elusive, as highly elevated
soluble CD44 associates with aggressive growth and bad prognosis
in cancer patients, and yet our previous results suggest that
recombinant CD44 administration can inhibit tumor xenograft
growth and angiogenesis [27]. We can speculate, that in cancer
patients with high sCD44, tumor cells have acquired resistance to
its inhibitory effects, while shedding of cell-surface bound CD44
confers significant selective advantage in tumor microenviron-
ment. In summary, given the facts that the expression of CD44
Figure 4. CD443MUT endocytosis by HUVEC. HUVEC were grown overnight on glass slides and incubated for 30 min at 37uC with 1 mM
unlabeled or Alexa Fluor 568-labeled CD443MUT or GST. Cells were analyzed by confocal microscopy. (A) Uptake of unlabeled CD443MUT by HUVEC
was detected with anti-CD443MUT mouse mAb 1A2 (green). Vimentin intermediate filaments were detected with rabbit polyclonal antibody (red).
Nuclei were stained with Hoechst (blue). Images are maximum intensity projections, generated along the z-axis of image stack. Scale bars, 10 mm. (B)
Internalization of directly Alexa Fluor 568-labeled CD443MUT by HUVEC (red). Vimentin (green) was detected with V9 mAb. Scale bars, upper and
middle panels 10 mm; insets 5 mm.
doi:10.1371/journal.pone.0029305.g004
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angiogenesis, our findings provide rationale for further functional
studies on the role of these proteins in EMT and angiogenesis.
Materials and Methods
Cell lines and antibodies
HUVEC and MLEC cells were grown in M199 medium
supplemented with 20% FBS, 4 mM L-glutamine, 50 mg/ml
heparin and 30 mg/ml EC growth supplement (ECGS, Upstate
Biotechnology, Lake Placid, NY, USA). MCF-7 cells (ATCC,
Manassas, VA, USA) were grown in RPMI, supplemented with
10%FBSand2 mML-glutamine.Anti-vimentin(V9),anti-Myc(A-
14) and anti-HDAC1 (H-11) antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Anti-vimentin rabbit
polyclonal (18-272-196311) was from Genway (San Diego, CA,
USA). Anti human-CD44 (2C5) was from R&D Systems (Minne-
apolis, MN, USA). Mouse anti-human CD44 (H4C4) was from
DSHB (University of Iowa, IA, USA). Anti CD443MUT mouse
mAb 1A2 (Figure S2)was generated by LabAS Ltd (Tartu, Estonia).
Anti-CD44 (MEM-263) was from EXBIO Praha (Czech Republic).
Anti-mouse PECAM-1 (MEC13.3), anti-mouse ICAM-2 (3C4) and
anti-EEA1 mAb were from BD Pharmingen (Palo Alto, CA, USA).
Rat anti-CD63/lamp-3 (R5G2) was from MBL International
(Woburn, MA, USA). Anti-Flag-M2 antibody was from Sigma.
Purification of recombinant proteins and fluorescence
labeling
CD44HABD and CD443MUT GST fusion-proteins were
purified as described [27]. CD44HABD and CD443MUT include
aa 21–132 of human CD44 protein. CD44HABD and -3MUT
were expressed using pET11c vector (Novagen). Urea dissolved
inclusion bodies were purified by gel filtration in Superdex-200HR
16/60 column (GE Healthcare, Uppsala, Sweden). Refolding was
performed by gradient dialysis into 50 mM Tris pH 8.0, 150 mM
NaCl and final dialysis into PBS. Endotoxin level was measured
using the Endosafe-PTS (Charles River, L’Arbresle, France).
Endotoxin values of CD443MUT batches were 22–93 EU/mg.
Human vimentin was expressed using pET15b vector (Novagen).
His-tagged vimentin was purified using Ni-affinity resin (Sigma)
Figure 5. Analysis of endocytosed CD443MUT localization. (A) HUVEC were incubated with A488-labeled CD44HABD or CD443MUT (green) in
the presence of CTxB-A555 (red) for 30 min. Nuclei were stained with Hoechst. Images show single confocal plane. Scale bars, 10 mm. (B)
Colocalization analysis of CD44HABD (HABD) and CD443MUT (3MUT) with CTxB. Left, the fraction of CTxB-vesicles colocalizing with HABD (n=39
cells) or 3MUT (n=38 cells). Middle, the number of CTxB-vesicles per cell; right, the number of HABD- or 3MUT-containing vesicles per cell. (C–E)
HUVEC were incubated with CD443MUT-A488 for 10 min after which CD443MUT-containing media was changed to 10% FBS HUVEC growth media
and cells were further incubated for 20 min. Then cells were fixed and stained with anti-EEA1 or anti-CD63 antibodies. (C) Localization of 3MUT- and
early endosomal marker EEA1-positive veicles after 10 min incubation in HUVEC. (D) Quantitation of EEA1-vesicles colocalizing with CD443MUT after
10 min incubation (n=26 cells) and after 20 min chase (n=40 cells; left). The number of EEA1- and 3MUT vesicles per cell (middle and left,
respectively). (E) Localization of internalized 3MUT and late endosomal protein CD63-positive vesicles. Scale bars, 2 mm (C) and 5 mm (E).
doi:10.1371/journal.pone.0029305.g005
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gradient dialysis into 10 mM Tris pH 8.0 with final dialysis into
10 mM phosphate buffer pH 7.4. Proteins were fluorescence-
labeled using sulfo-NHS-Alexa Fluor 488 or 2568 protein labeling
kit (Molecular Probes, Eugene, OR, USA).
GST pull-down, immunoprecipitation and cell surface
biotinylation
Adherent cells were rinsed with ice-cold PBS and lysed on ice in
50 mM Tris pH 8.0, supplemented with protease inhibitor
cocktail (PIC; Roche, Mannheim, Germany). Lysate was centri-
fuged at 14000 rpm for 30 min at 4uC. Pellet was solubilized in
2% CHAPS, 50 mM Tris pH 8.0, 50 mM NaCl, PIC buffer and
centrifuged at 14000 rpm for 10 min at 4uC. Supernatant was
precleared by incubation with GST-bound glutathione-sepharose
4FF beads (Amersham Biosciences, Uppsala, Sweden). Precleared
lysate was incubated overnight at 4uC with 10 mg GST, GST-
tagged CD44HABD or CD443MUT immobilized onto glutathi-
one beads. After washes with 50 mM Tris pH 8.0, 150 mM NaCl,
PIC buffer, beads were eluted with 20 mM reduced glutathione in
50 mM Tris pH 8.0. Eluates were precipitated with 20% TCA,
precipitate was washed with cold acetone and aspirated dry. For
MALDI-TOF MS analysis of tryptic peptides, protein samples
were alkylated and visualized by silver staining on SDS-PAGE.
For biotinylation, adherent cells were incubated with 1 mM EZ-
Link Sulfo-NHS-LC-biotin (Pierce, Rockford, IL, USA) in PBS-
0.05% NaN3 for 30 min on ice, washed with 100 mM glycine-PBS
and lysed as described above. For IP of endogenous proteins,
adherent cells were rinsed with cold PBS and lysed in 50 mM Tris
pH 8.0, 50 mM NaCl, 1% CHAPS, PIC buffer. Lysate was
centrifuged at 14000 rpm for 30 min at 4uC. Supernatant was pre-
cleared with anti-HDAC1 immobilized onto protein A/G
sepharose beads (Amersham Biosciences) at 4uC. Precleared lysate
was incubated with anti-HDAC1 or anti-CD44 (MEM-263)
antibodies immobilized onto protein A/G beads overnight at
4uC. Beads were washed with lysis buffer and bound proteins were
eluted with 0.5 M glycine (pH 2.5). Finally, pH of eluates was
adjusted with 1 M Tris pH 8.0 and they were analyzed by
immunoblotting using anti-CD44 (2C5) or rabbit anti-vimentin
antibody. For IP of over-expressed proteins, adherent cells were
rinsed in cold PBS, lysed in lysis buffer containing 40 mM Hepes
pH 7.4, 120 mM NaCl, 1 mM EDTA, 0.6% CHAPS and PIC.
Lysates were centrifuged at 14000 rpm for 30 min at 4uC.
Supernatants were incubated with anti-Flag-M2 affinity gel
(Sigma) overnight at 4uC, beads were washed with lysis buffer
and bound proteins were eluted with 26Laemmli sample buffer.
Eluted protein complexes were analyzed by immunoblotting with
anti-Flag-M2 or anti-Myc.
Isothermal titration calorimetry and surface plasmon
resonance
ITC measurements were performed on a Nano-2G instrument
(TA Instruments, New Castle, DE, USA). Experiments were
performed in 50 mM Tris, 150 mM NaCl, pH 8.0 at 25uC. The
Figure 6. Vimentin dependent endocytosis of CD443MUT. MLEC were isolated either from wild-type (WT) or vimentin-null mice. (A)
Immunoblot of WT of Vim2/2 MLEC lysates with anti-vimentin rabbit polyclonal antibody. (B) FACS analysis of MLEC for cell surface markers with
either anti-PECAM-1, anti-ICAM-2 or anti-CD44 antibodies (black lines). Gray lines, no primary antibody controls. (C) MLEC-s were incubated with
CD443MUT-A568 (red) for 30 min and processed for immunofluorescence. Scale bars, upper panels 10 mm; insets 5 mm.
doi:10.1371/journal.pone.0029305.g006
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syringe size – 250 ml, stirring rate – 250 rpm, injection volume –
10 ml, time interval between injections – 300 s. Titration data were
analyzed by non-linear fitting (SigmaPlot 10). SPR measurements
were performed on Biacore3000 (GE Healthcare). Vimentin was
covalently coupled to CM5 chip using amine coupling kit (GE
Healthcare). In association phase, CD443MUT concentrations
0.46–123 mM were injected over the chip surface. In the
dissociation phase, the sensor chip surface was eluted with buffer
50 mM Tris, 150 mM NaCl, pH 8.0. The association rate
constants and the dissociation rate constants were estimated using
BIAevaluation software (GE Healthcare) using a parallel binding
model, A+B1 «AB1, A+B2 « AB2. Kd values were also
determined from analysis of the equilibrium data using equation 1:
DR=(DRmax?x)/(Kd+x)+(c ? x), where x – concentration of the
injected protein, DR – the increase of the response value at
equilibrium, DRmax – capacity of the immobilised vimentin to bind
a protein (the number of binding sites), and c describes weak or
non-specific interaction.
Displacement assays
Adherent cells were harvested from culture plates with 5 mM
EDTA in PBS. Proteins were iodinated with
125I by using Iodo-
beads (Pierce). Cells were resuspended in incubation buffer
20 mM Tris-HCl pH 7.5, 5 mM MgCl2, 30 mM NaCl, 3 mM
CaCl2 or DMEM, 25 mM HEPES, 0.1% BSA. Cell suspension
was transferred into 96-well microtitre plate in 100 ml volume.
Unlabeled protein at different concentrations and
125I labeled
protein in 20 ml volume of incubation buffer was added into wells.
Reactions were incubated overnight at 4uC and stopped by
filtration through GF/B filters blocked with 0.1% BSA-PBS,
followed by washes with cold PBS. Filters were transfered into
5 ml vials and bound radioactivity was measured using gamma
counter (PerkinElmer).
FACS analyses
For CD443MUT cellular binding, HUVEC were serum starved
6 h and then induced for 30 min at 37uC with 10 ng/ml VEGF-
165 in media containing 0.5% FBS. Alexa Fluor 488-conjugated
CD443MUT or GST was added into media at 25 mg/ml and cells
were incubated for 1 h on ice. Cells were harvested from culture
plates by scraping. After washes with 0.1% BSA-PBS, cells were
fixed in 4% formaldehyde-PBS and analyzed using FACSCalibur
flow cytometer (BD Biosciences).
DNA constructs and transfection
Full-length vimentin was PCR amplified from human vimentin
cDNA and inserted into EcoRI/SacII site of pcDNA3.1/
MycHisB vector (Invitrogen). Vimentin deletion mutants con-
taining amino acids 1-96 (VIM1-96), 1-245 (VIM1-245), 246-466
(VIM246-466) and 97-466 (VIM97-466) were PCR amplified
from human vimentin cDNA using oligonucleotide pairs
containing EcoRI/NotI sites. PCR fragments were inserted into
EcoRI/NotI site of pcDNA3.1/MycHisB vector. Vimentin-GFP
(GFP, green fluorescent protein) constructs were created by
inserting EcoRI/SacII fragment from respective vimentin-
pcDNA3.1/MycHisB constructs into pEGFP-N1 vector. Vimen-
tin deletion mutant containing aa 407-466 (VIM407-466) was
PCR amplified from human vimentin cDNA and inserted into
EcoRI/SalI site of pEGFP-C2 vector. For creating Flag-tagged
CD44 DNA construct, full-length CD44 was PCR amplified from
human standard CD44 isoform cDNA and inserted into EcoRI/
NotI site of pCMV-Tag4a vector (Stratagene). MCF-7 cells were
transfected using 1:2 DNA:PEI ratio. Transfected cells were
grown at 37uC for 24 h. GST pull-down was performed as
described above.
Mouse lung endothelial cells
Wild-type MLEC were isolated from C3H mouse strain (The
Jackson Laboratory) and vimentin2/2 from Vim1/Vim1 mice
[31] obtained from EMMA (CNRS/CDTA, Orleans, France).
Lungs from three 6–8 week old mice were dissected and finely
minced with scissors on a dry culture dish. Lung pieces were put
into 20 ml pre-warmed 0.2% collagenase-I (Sigma) in PBS and
incubated with gentle agitation for 45 min at 37uC. Collagenase
digested lung suspension was triturated through 100 mm cell
strainer (BD Biosciences). Cell suspension was centrifuged 8 min
400 g at 4uC. Cell pellet was resuspended in 2 ml 0.1% BSA-PBS.
Cells were sorted by incubation for 15 min at RT with sheep anti-
rat IgG Dynabeads (Dynal, Norway) coated with rat anti-mouse
CD31 (MEC13.3) and rat anti-mouse ICAM-2 (3C4) antibodies.
Bead-bound cells were separated using a magnetic rack and
washed five times with M199 medium containing 10% FBS. After
separation, cells were plated onto dish and grown in M199
containing 10 mM HEPES, 20% FBS, 4 mM L-glutamine and
supplemented with 50 mg/ml Heparin, 30 mg/ml ECGS and
penicillin-streptomycin.
Internalization assay, immunofluorescence microscopy
and image processing
For internalization assays, cells on 8-well slide (BD Falcon)
were incubated at 37uC with CTxB-Alexa 555 (Invitrogen) and/
or CD44HABD-proteins at 13 mg/ml (<1 mM) in 0.5% FBS
containing media for 10 or 30 min. After 10 min uptake, cells
were washed with PBS two to three times and media was changed
to 10% FBS containing M199 HUVEC growth media and slides
were incubated for 20 or 50 min at 37uC. After incubations cells
were washed and fixed with 4% formaldehyde-PBS on for 10 min
on ice and for 10 min at RT. Cells were permeabilized using
0.1% Triton X-100 in 0.1% BSA-PBS. Antibodies were diluted in
0.1% BSA-PBS. Secondary antibody dilutions were supplement-
ed with 10 mg/ml Hoechst 33258 (Sigma). Slides were mounted
in Mowiol 4–88 (Sigma-Aldrich, St Louis, MO, USA). Confocal
fluorescent imaging was performed using Zeiss LSM510 micro-
scope with 663/1.4 oil immersion objective in multi-channel
mode (Carl Zeiss MicroImaging, Germany). Images were
prepared using Imaris 6.4 software (Bitplane, Zurich, Switzer-
land). For quantitation of endocytosis and vesicular colocaliza-
tion, single slices from the middle plane of the cell were semi-
automatically selected from confocal image stacks using Fiji
package (http://pacific.mpi-cbg.de/wiki/index.php/Fiji). Cell-
profiler 2.0 (r10415) software was used ror image segmentation
and automated analysis [54]. Endosomal outlines were identified
using Otsu global treshold, then endosomal marker/tracer object
outlines were used to create a mask to identify colocalizing
CD44HABD- or CD443MUT objects. Within these objects
correlation was measured between endocytosis marker and
CD44, and objects showing positive correlation were finally
counted as colocalizing. For calculation of average correlation
coefficient and 95% confidence interval, individual object
coefficients were transformed to z scores.
Statistical analysis of data
Data represent mean 6 SE. Statistical analysis and non-linear
fitting of data was performed using GraphPad Prism 5 software
(San Diego, CA, USA).
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Figure S1 Cell-surface expression of overexpressed
vimentin in MCF-7 cells. Vimentin- or empty vector
transfected MCF-7 cells were subjected to cell surface biotinylation
(see Materials and Methods). Lysates were immunoprecipitated
with anti-vimentin antibody. Lysates and immunoprecipitates
were analyzed by WB using strepavidin-HRP (upper panel) or
anti-vimentin antibody (lower panel). Arrows indicate the location
of full length vimentin.
(TIF)
Figure S2 Characterization of anti-CD443MUT mouse
mAb 1A2. (A) ELISA analysis of serially diluted 1A2 mAb
(3.1 mg/ml) of rat serum2, rat serum+CD443MUT- or
CD443MUT-coated wells. PBS, no primary antibody control.
(B) Microplate wells were coated with different concentrations of
CD443MUT mixed with rat serum and analyzed by ELISA using
1A2 mAb at 1:400 dilution. (C) Wells were coated with CD44
peptides and analyzed by ELISA using 1A2 mAb at 1:50000
dilution. (D) Amino acid alignment of CD44HABD, CD443MUT
and peptides used for epitope mapping. Amino acid numbering is
according to human CD44; mutated positions are indicated in
green (wild-type amino acids) or red (mutant amino acids). Bars,
mean 6 SD.
(TIF)
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